Quick Answer
Rallybio Corp reported R&D Expense of $19.60 million for fiscal year 2025.
Rallybio Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $19.60M | -52.8% |
| 2024 | $41.51M | -22.5% |
| 2023 | $53.54M | +31.6% |
| 2022 | $40.69M | +51.2% |
| 2021 | $26.91M | +52.6% |
| 2020 | $17.63M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.14M | -49.7% | -31.8% |
| June 30, 2025 | $6.07M | -53.1% | +6.1% |
| March 31, 2025 | $5.72M | -55.7% | -30.5% |
| September 30, 2024 | $8.24M | -38.0% | -36.4% |
| June 30, 2024 | $12.95M | -1.4% | +0.1% |
| March 31, 2024 | $12.94M | +15.5% | -2.6% |
| September 30, 2023 | $13.29M | +9.7% | +1.2% |
| June 30, 2023 | $13.13M | +29.5% | +17.2% |
- Rallybio Corp showed a decrease of -52.8% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Rallybio Corp’s r&d expense has grown by 11.2% (from $17.63 million to $19.60 million).
- The most recent figure is from Rallybio Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: